-
Summary of adverse events for patients with severe renal impairment<sup>a</sup>.
Summary of adverse events for patients with severe renal impairmenta. -
r37980778c78--6042153680df7d78736b088242c2ea45
Meta-analysis and meta-regression of effective sizes in adverse events. -
HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with R...
This study evaluated the interferon-free, oral combination of deleobuvir (non-nucleoside HCV NS5-RNA-polymerase inhibitor) and faldaprevir (HCV NS3/4A-protease inhibitor) with... -
Adverse event detection by medical record review is reproducible, but the ass...
ObjectiveTo assess the reproducibility of adverse event evaluation by a medical record review committee.DesignCross-sectional reanalysis of medical records.InterventionReviewers... -
Sensitivity analysis of overall modelled costs with 10%, 3% or no discount fa...
Sensitivity analysis of overall modelled costs with 10%, 3% or no discount factor on costs per year. -
r37980778c78--b2c196c9c61d330e812bfc9df02c2f92
Cytogenetic features at baseline in del(5q) patients. -
Potential risk factors associated with human alveolar echinococcosis: Systema...
BackgroundHuman alveolar echinococcosis (AE) is a severe zoonotic disease caused by the metacestode stage of Echinococcus multilocularis. AE is commonly associated with a long... -
Summary of most frequent adverse events with WHO grade 3 or 4 for patients wi...
Summary of most frequent adverse events with WHO grade 3 or 4 for patients with relapsed or refractory peripheral T-cell lymphoma treated by various salvage therapy. -
r37980778c78--d482078afcc8257e6cda063d25fd39a0
Number of AEs and SAEs per apparatus and clinical management. -
Average AE-related costs in the year of diagnosis and the two subsequent years.
Average AE-related costs in the year of diagnosis and the two subsequent years. -
r37980778c78--6da394121b2fb0cc409ad27c7e3c4e2c
PurposeThis systematic review with network meta-analysis compared the efficacy and safety of currently licensed second-line treatments in patients with late stage non-small cell... -
r37980778c78--c3c4dbd336f11dd6a60f989de3391137
Comparison of different clinical endpoints among CM, Cap or other regimens based MCT schemes. -
Protective effect of different extracts and fractions of <i>P</i>. <i>niruri<...
Protective effect of different extracts and fractions of P. niruri on CCl4 induced toxicity in clone-9 cell line. -
Assessment of a prognostic model, PSA metrics and toxicities in metastatic ca...
BackgroundPrognostic models in metastatic castrate resistant prostate cancer (mCRPC) may have clinical utility. Using data from PDS, we aimed to 1) validate a contemporary... -
Characteristics of persons experiencing homelessness for 11 program sites fro...
Characteristics of persons experiencing homelessness for 11 program sites from July 2011-June 2015. -
Trial characteristics: <i>A</i>. <i>Paniculata</i> plus usual care versus Usu...
Trial characteristics: A. Paniculata plus usual care versus Usual care (n = 9). -
Summary of included studies.
*Sample size calculated excluding non-active controls; brackets indicate final number used in evaluation, if reported. APAI: Acholi Psychosocial Assessment Instrument; BASC:...
